Clinical Trials in Idiopathic Pulmonary Fibrosis

This chapter examines the design and execution of clinical trials for nintetanib in the treatment of idiopathic pulmonary fibrosis, emphasizing participant selection criteria, diagnostic challenges, and primary endpoints. It highlights the significance of measuring lung function and the implications of acute exacerbations on patient outcomes.